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Background: The incidence of reported cases of equine herpesvirus myeloencephalopathy (EHM) caused by infection
with neuropathogenic strains of equine herpesvirus 1 (EHV-1) has markedly increased over the last decade in many
Western countries. The purpose of this study was to estimate the prevalence of the neuropathogenic (G2254) and
non-neuropathogenic (A2254) variants of EHV-1 among isolates associated with abortions in Polish stud farms.
Results: The results of polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and sequencing
were consistent, and showed that two out of 64 abortions (3.1%) were induced by the neuropathogenic genotype
G2254. All remaining 18 EHV-1 positive abortion cases (28.1%) were caused by the non-neuropathogenic genotype
A2254.
Conclusions: Most of the abortions in mares in Poland from 1999 to 2012 were associated with non-neuropathogenic
strains of EHV-1. However, the presented data indicate that the neuropathogenic genotype of the virus is also present in
Polish stud farms. Such a presence suggests that the future emergence of EHM in Poland is probable.
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Equine herpesvirus 1 (EHV-1) is a double-stranded
DNA virus that occurs worldwide in all breeds of horses
[1,2]. Infections caused by EHV-1 are important as clin-
ical outbreaks of the disease still occur, despite prevent-
ive and control measures being taken [3,4]. Exposure to
EHV-1 can cause upper respiratory tract infection in
foals and young horses. In pregnant mares, the virus can
be transferred across the uteroplacental barrier and in-
fect the fetus, which can lead to late-gestation abortion.
EHV-1 can also migrate with infected blood leukocytes
to the central nervous system and replicate in endothe-
lial cells of arterioles in the spinal cord and brain,
causing vasculitis and thrombosis [5]; this syndrome
is known as equine herpesvirus myeloencephalopathy
(EHM). Previous research has shown that the neuro-
pathogenicity of EHV-1 strains is strongly associated
with a single point mutation in the open reading frame* Correspondence: jrola@piwet.pulawy.pl
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unless otherwise stated.(ORF) 30 of the gene encoding viral DNA polymerase
[6-8]. This mutation is a single nucleotide adenine to
guanine substitution at nucleotide 2,254, corresponding
to an asparagine to aspartic acid substitution. Addition-
ally, two other studies revealed that another nucleotide
substitution at nucleotide 2,258 of ORF30 could possibly
be associated with neuropathogenicity [6,9].
Although the clinical form of EHM is less frequently
observed than the other types of EHV-1 infection, it can
cause serious economic losses in breeding horses and
have a very negative impact on the functioning of veter-
inary hospitals, riding schools, and racetracks [4,3,10,11].
Moreover, recent data from the United States of
America (US) showed that neuropathogenic strains of
EHV-1 could become an important causative agent of
abortions in mares even in the absence of actual clinical
signs of EHM or respiratory disease [9].
In Poland, EHV-1 abortion outbreaks in mares have
been reported several times since the early 1950s
[12-15]. However, there are no data on the occurrence
of neuropathogenic EHV-1 strains in Poland. The pur-
pose of this study was to determine the prevalence ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Polish ORF30 genotype of EHV-1 isolates by
PCR-RFLP
Strain designationa Genotype at position 2254 Regionb
PL/1999/I A 2254 LU
PL/1999/II A 2254 MA
PL/2001/I A 2254 LU
PL/2002/I A 2254 MA
PL/2003/I A 2254 WP
PL/2004/I A 2254 LU
PL/2004/II A 2254 PM
PL/2005/I A 2254 WM
PL/2006/I A 2254 MP
PL/2006/II A 2254 LU
PL/2007/I A 2254 MA
PL/2008/I A 2254 DS
PL/2009/I A 2254 SL
PL/2009/II G 2254 LU
PL/2010/I A 2254 MA
PL/2010/II G 2254 SL
PL/2010/III A 2254 LU
PL/2011/I A 2254 MP
PL/2012/I A 2254 MA
PL/2012/II A 2254 LU
aBased on the year of isolation.
bVoivodship SL-Silesian; MA-Masovian; WM-Warmian-Masurian.
LU-Lublin; MP-Lesser Poland; PM-Pomeranian; DS-Lower Silesian.
WP-Greater Poland. The regions are described in detail at:
http://en.wikipedia.org/wiki/Voivodeships_of_Poland.
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strains of EHV-1 isolated from abortion cases in Poland.
Methods
Samples
We tested tissue samples (lung, liver, spleen, heart, kid-
ney, and placenta, if delivered) from 64 aborted fetuses
that were delivered to the Department of Virology of the
National Veterinary Research Institute in Pulawy be-
tween 1999 and 2012. The whole fetuses or fetal organs
came from horse studs located in different regions of
Poland. None of the animals had been vaccinated against
EHV-1, and none of the studs had a history of respira-
tory and neurological disease. Necropsy reports revealed
that all 64 abortions occurred during the third trimester
of pregnancy. A variety of macroscopic lesions were ob-
served in most cases, including a large amount of pleural
fluid, hepatic necrosis, and pulmonary oedema. No
histological investigation was done. Organ samples from
aborted fetuses were stored at −70°C until further
processing.
Two grams of each tissue sample was used for prepar-
ation of 10% (w/v) suspension in Eagle’s Minimum Essential
Medium (Sigma-Aldrich), supplemented with 1% antibiotic
solution (Antibiotic Antimycotic Solution 100x, Sigma-
Aldrich) using ULTRA-TURRAX® homogenizer. Tissue
homogenates were centrifuged at 1,700 x g for 10 min, and
then supernatants from the same fetus were pooled to-
gether and stored at −70°C until testing.
DNA extraction
DNA was extracted from every pool of tissue supernatant
using a phenol-chloroform-isoamyl alcohol mixture.
PCR testing
The DNA obtained from tissue homogenates was tested
for the presence of EHV-1 and EHV-4 using primers for
glycoprotein B previously described by Kirisawa et al.
(EHV1/4 Forward: 5′-CTT GTG AGA TCT AAC CGC
AC-3′[1477-1496/1468-1487], EHV-1 Reverse: 5′-GCG
TTA TAG CTA TCA CGT CC-3′[1936–1917], EHV-4
Reverse: 5′-CCT GCA TAA TGA CAG CAG TG-
3′[2410–2391]) [16].
Virus isolation
EHV-1 was isolated in 25-cm2 tissue culture flasks contain-
ing monolayers of RK13 cells. Flasks were inoculated and
checked daily for appearance of cytopathic effect (CPE).
CPE-positive flasks were frozen and stored at −70°C.
Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP)
PCR-RFLP neuropathogenic/non-neuropathogenic dis-
crimination testing was performed on EHV-1-positivesamples. PCR amplification of a 380-bp fragment of
ORF30 was based on a modified protocol described by
Allen [17]. A 25-μl reaction mix was prepared for PCR
containing 0.05 U/μl AccuTaq LA DNA Polymerase,
200 μM of deoxynucleotide triphosphate mix, 1 × PCR
buffer, 400 nM of the primer ORF30-Forward (5′-GTG
GAC GGT ACC CCG GAC-3′[2005–2022]) and
ORF30-Reverse (5′-GTG GGG ATT CGC GCC CTC
ACC-3′[2384–2364]) and 2.5 μl DNA template, sus-
pended in RNAse-DNAse-free water. The reaction was
run in a Biometra Thermocycler (Biometra, Germany)
under the following conditions: initial denaturation at
94°C for 3 min, followed by 35 cycles of denaturation at
94°C for 30 s, annealing at 60°C for 1 min, and elong-
ation at 72°C for 30 s.
PCR products were digested with SalI enzyme [recogni-
tion site: 5′…G↓TCGAC…3′] (EURx, Poland). Digestion
was performed in a 50-μl reaction mixture containing
10 μl of PCR product, 5 μl 10x Buffer High, 0.5 μl 100x
BSA (EURx), and 1 μl SalI enzyme, suspended in nuclease
free water. Digestion was run at 37°C for 2 h in a thermo-
cycler. Products were visualized by electrophoresis on 1.5%
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positive control: Ab4 (neuropathogenic strain) and V592
(non-neuropathogenic strain).
Sequencing
All positive samples were confirmed by sequencing the
380-bp ORF30 fragment using the Sanger method at the
Institute of Biochemistry and Biophysics Polish Academy
of Science (Warsaw, Poland). Nucleotide sequences were
assembled and aligned using Molecular Evolutionary
Genetics Analysis (MEGA) version 5.0.5. The nucleotide
sequences reported in this study were submitted to
GenBank under the accession numbers KR080374-
KR080393.
Results
PCR analysis using Kirisawa’s PCR primers showed that
20 pooled samples were EHV-1 positive, but no samples
were EHV-4 positive. Virus isolation was successful in
all PCR positive samples, with a clearly visible CPE
developing within 3–5 days after inoculation of cells
(Table 1).
Amplification using ORF30-specific PCR and further
digestion of PCR products with SalI enzyme showed that
two of the 20 EHV-1 positive isolates were the neuro-
pathogenic variant G2254 (10% of EHV-1 positive iso-
lates, and 3.1% of total abortion cases), whereas 18 were
the non-neuropathogenic variant A2254 (90% of EHV-1
positive isolates, and 28.1% of all abortion cases).
Comparative nucleotide sequence analysis of the
380-bp fragment gene encoding the catalytic subunit
(ORF30) of the viral DNA polymerase confirmed theFigure 1 Sequence analysis of ORF30 of Polish EHV-1 isolates (PL/1999/I–PL
site SalI enzyme.presence of guanine at nucleotide position 2,254 in two
isolates. The other EHV-1 isolates encoded adenine at the
position 2,254 and were classified as non-neuropathogenic
variants. No nucleotide substitution was found at
position 2,258. The consensus alignment indicated that
partial ORF30 sequences were identical to the se-
quences of appropriate reference strains of EHV-1: Ab4
(neuropathogenic) and V592 (non-neuropathogenic)
(Figure 1).
Discussion
There have been no previous reports of EHM outbreaks
in Poland, and no potentially neuropathogenic variants
of EHV-1 have previously been identified [18]. We have
shown, for the first time, that the neuropathogenic geno-
type of EHV-1 circulates in the horse population in
Poland. There was a clear predominance of the non-
neuropathogenic (90% of EHV-1 positive cases) over the
neuropathogenic EHV-1 genotype (10% of EHV-1 posi-
tive cases) as a causative agent of abortions in Polish
stud farms. This proportion is similar to the results of
recent studies in which abortion was associated with the
neuropathogenic variant of EHV-1 in 0.9% of abortion
cases in Japan [19], 7% in Argentina [20], 8.9% in Central
Kentucky of the US [9], 10.6% in Germany [21], and
25.9% in France [22].
In contrast to a few abortion outbreaks in Argentina
and Germany that were associated with neurological
signs in mares, there were no clinical signs indicating
EHM in any case of aborted fetuses tested in this
study. These results are not unusual as previous
studies have proved that although the presence of the/2012/II). Variable position 2,254 is shaded in the box marked restriction
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EHM cases, it is not the only factor that determines the
appearance of neurological disease in infected horses
[23,24]. For example, a German study found that only
two out of seven abortion cases caused by neuropatho-
genic EHV-1 strains were associated with EHM signs in
pregnant mares [21]. Some studies have associated EHM
with the presence of another substitution (adenine to
cytosine) in ORF30 at the 2,258 position [9,21]; however,
this was not detected in our study.
The EHV-1 isolates possessing a nucleotide substitu-
tion from A to G at the 2,254 position were detected in
two distant provinces of Poland, hence it is unlikely that
the abortions were caused by the same strain of the
virus. As this study concentrated on abortion cases, only
a fraction of the total EHV-1 infections in Poland were
analyzed, whereas a previous study by Pronost et al.
showed that the G2254 genotype could also be associ-
ated with respiratory disease [22]. It is also possible that
some of our cases were caused by mixed infection with
two viral strains. Allen et al. described the occurrence
of dual infections in the Thoroughbred broodmare
population, with both neuropathogenic and non-
neuropathogenic strains involved [25]. A similar situ-
ation took place in the case of horses infected after
natural exposure at a racetrack in California [26].
Unfortunately, the diagnostic techniques used in our
study were not able to detect simultaneous infection
with both genotypes.
Finally, it cannot be excluded that EHM cases may
have already appeared in Poland, but were either not
reported or not identified properly by veterinarians. Even
if this assumption is wrong, the fact that the G2254
ORF30 variant of EHV-1 is present in the horse popula-
tion means that the risk of EHM outbreaks in Poland
should be taken into consideration.
Conclusion
The presented data demonstrate that the neuropatho-
genic genotype of EHV-1 is present in Polish stud farms.
Of the 20 EHV-1 abortion isolates, the vast majority
belonged to the non-neuropathogenic marker A2254
(18 out of 20 isolates, which was 90%), with only two out
of the 20 isolates (10%) identified as the neuropathogenic
genotype G2254. However, the presence of neuropatho-
genic EHV-1 strains in Polish studs suggests that the
emergence of EHM cases in Poland is probable.
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